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Résumé en
anglais
Background Resistance to chemotherapy remains one of the principle obstacles to
the treatment of colon cancer. In order to identify the molecular mechanism of this
resistance, we investigated the role of the steroid and xenobiotic receptor (SXR) in
the induction of drug resistance. Indeed, this nuclear receptor plays an important
role in response to xenobiotics through the upregulation of detoxification genes.
Following drug treatments, SXR is activated and interacts with the retinoid X
receptor (RXR) to induce expression of some genes involved in drug metabolism
such as phase I enzyme (like CYP), phase II enzymes (like UGT) and transporters
(e.g. MDR1). Results In this study, we have shown that endogenous SXR is activated
in response to SN-38, the active metabolite of the anticancer drug irinotecan, in
human colon cancer cell lines. We have found that endogenous SXR translocates
into the nucleus and associates with RXR upon SN-38 treatment. Using ChIP, we
have demonstrated that endogenous SXR, following its activation, binds to the
native promoter of the CYP3A4 gene to induce its expression. RNA interference
experiments confirmed SXR involvement in CYP3A4 overexpression and permitted
us to identify CYP3A5 and MRP2 transporter as SXR target genes. As a
consequence, cells overexpressing SXR were found to be less sensitive to irinotecan
treatment. Conclusions Altogether, these results suggest that the SXR pathway is
involved in colon cancer irinotecan resistance in colon cancer cell line via the
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